Hofmeyr G J, Atallah A N, Duley L
University of the Witwatersrand, University of Fort Hare, Eastern Cape Department of Health, Frere and Cecilia Makiwane Hospitals, Private Bag X 9047, East London, Eastern Cape, South Africa 5200.
Cochrane Database Syst Rev. 2006 Jul 19(3):CD001059. doi: 10.1002/14651858.CD001059.pub2.
Pre-eclampsia and eclampsia are common causes of serious morbidity and death. Calcium supplementation may reduce the risk of pre-eclampsia through a number of mechanisms, and may help to prevent preterm labour.
To assess the effects of calcium supplementation during pregnancy on hypertensive disorders of pregnancy and related maternal and child outcomes.
We searched the Cochrane Pregnancy and Childbirth Group Trials Register (February 2006), the Cochrane Central Register of Controlled Trials (The Cochrane Library, 2005, Issue 4), and contacted study authors.
Randomised trials comparing at least one gram daily of calcium during pregnancy with placebo.
We assessed eligibility and trial quality, extracted and double-entered data.
Twelve studies of good quality were included. The risk of high blood pressure was reduced with calcium supplementation rather than placebo (11 trials, 14,946 women: relative risk (RR) 0.70, 95% confidence interval (CI) 0.57 to 0.86). There was also a reduction in the risk of pre-eclampsia associated with calcium supplementation (12 trials, 15,206 women: RR 0.48, 95% CI 0.33 to 0.69). The effect was greatest for high-risk women (5 trials, 587 women: RR 0.22, 95% CI 0.12 to 0.42), and those with low baseline calcium intake (7 trials, 10,154 women: RR 0.36, 95% CI 0.18 to 0.70). The composite outcome maternal death or serious morbidity was reduced (4 trials, 9732 women; RR 0.80, 0.65 to 0.97). Almost all the women in these trials were low risk and had a low calcium diet. Maternal deaths were reported in only one trial. One death occurred in the calcium group and six in the placebo group, a difference which was not statistically significant (RR 0.17, 95% CI 0.02 to 1.39). There was no overall effect on the risk of preterm birth (10 trials, 14,751 women: RR 0.81, 95% CI 0.64 to 1.03), or stillbirth or death before discharge from hospital (10 trials 15,141 babies; RR 0.89, 95% CI 0.73 to 1.09).Blood pressure in childhood has been assessed in one study: childhood systolic blood pressure greater than 95th percentile was reduced (514 children: RR 0.59, 95% CI 0.39 to 0.91).
AUTHORS' CONCLUSIONS: Calcium supplementation appears to almost halve the risk of pre-eclampsia, and to reduce the rare occurrence of the composite outcome 'death or serious morbidity'. There were no other clear benefits, or harms.
先兆子痫和子痫是导致严重发病和死亡的常见原因。补钙可能通过多种机制降低先兆子痫的风险,并有助于预防早产。
评估孕期补钙对妊娠高血压疾病及相关母婴结局的影响。
我们检索了Cochrane妊娠与分娩组试验注册库(2006年2月)、Cochrane对照试验中心注册库(Cochrane图书馆,2005年第4期),并联系了研究作者。
比较孕期每日至少补钙1克与安慰剂的随机试验。
我们评估了纳入标准和试验质量,提取并双人录入数据。
纳入了12项高质量研究。补钙组而非安慰剂组的高血压风险降低(11项试验,14946名女性:相对危险度(RR)0.70,95%置信区间(CI)0.57至0.86)。补钙还降低了先兆子痫的风险(12项试验,15206名女性:RR 0.48,95%CI 0.33至0.69)。对高危女性(5项试验,587名女性:RR 0.22,95%CI 0.12至0.42)和基线钙摄入量低的女性(7项试验,10154名女性:RR 0.36,95%CI 0.18至0.70)效果最为显著。孕产妇死亡或严重发病的综合结局降低(4项试验,9732名女性;RR 0.80,0.65至0.97)。这些试验中的几乎所有女性均为低风险且钙饮食摄入低。仅在一项试验中报告了孕产妇死亡情况。补钙组有1例死亡,安慰剂组有6例死亡,差异无统计学意义(RR 0.17,95%CI 0.02至1.39)。对早产风险(10项试验,14751名女性:RR 0.81,95%CI 0.64至1.03)或死产或出院前死亡(10项试验,15141名婴儿;RR 0.89,95%CI 0.73至1.09)无总体影响。一项研究评估了儿童期血压:儿童期收缩压高于第95百分位数的情况减少(514名儿童:RR 0.59,95%CI 0.39至0.91)。
补钙似乎可使先兆子痫的风险几乎减半,并降低“死亡或严重发病”这一罕见综合结局的发生率。未发现其他明显的益处或危害。